Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-cell receptors (TCRs) recognizing Dermatophagoides pteronyssinus allergen-derived epitopes are specialized heterodimeric surface proteins, typically composed of alpha and beta chains, that mediate the adaptive immune response to house dust mite (HDM) allergens. These receptors specifically identify peptide fragments from major allergens such as Der p 1, Der p 2, and Der p 23 when presented by Major Histocompatibility Complex (MHC) molecules on antigen-presenting cells (Cabrera et al., 2023, J. Allergy Clin. Immunol.). In sensitized individuals, the engagement of these TCRs predominantly drives the differentiation and activation of Th2 cells, which secrete pro-inflammatory cytokines like IL-4 and IL-13, leading to IgE production and eosinophilic inflammation (Wambre et al., 2017, Science Translational Medicine). This molecular recognition is the primary driver of allergic diseases, including asthma and rhinitis. Therapeutic strategies targeting these TCRs include allergen immunotherapy (AIT), which aims to desensitize the immune system by inducing T-cell anergy or promoting the expansion of allergen-specific regulatory T cells (Tregs) that suppress the allergic cascade (Akdis & Akdis, 2014, Nature Reviews Drug Discovery). Recent advancements also explore TCR-engineered T cells and soluble TCR-mimetic molecules to precisely modulate the immune response to HDM allergens.
Modulation of T-cell signaling to induce peripheral tolerance, promote T-regulatory cell differentiation, and reduce Th2-mediated inflammation.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor recognizing Dermatophagoides pteronyssinus allergen-derived epitopes (TCR-Der p).